UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | J | K | M | N | O | P | S | V | W
Number of items: 95.

A

Al-Azraqi, A; Angus, B; Gokul, S; Sinha, D; Calvert, AH; Lunec, J; (1999) Bcl-2 expression is a potential prognostic co-factor with P53-mutation status in epithelial ovarian carcinoma. British Journal of Cancer , 80 178-.

Al-Mufti, RAM; Pedley, RB; Marshall, D; Begent, RHJ; Winslet, MCAH; K, EF; (1999) In vitro assessment of lipiodol targeted radiotherapy for primary and metastatic liver cancers. British Journal of Cancer , 79 pp. 1665-1671.

Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, PJ; Endicott, JA; Gibson, AE; ... Schultz, R; + view all (1999) In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors. British Journal of Cancer , 80 110-.

B

Batey, MA; Wright, JG; Simmonds, D; Proctor, M; Chapman, F; Fishwick, K; Azzabi, A; ... Boddy, AV; + view all (1999) Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer. British Journal of Cancer , 80 259-.

Bentzen, SM; Saunders, MI; Dische, S; (1999) Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiotherapy and Oncology , 53 pp. 219-226.

Brooks, N; McHugh, PJ; Lee, M; Hartley, JA; (1999) The role of base excision repair in the repair of DNA adducts formed by a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size. ANTI-CANCER DRUG DES , 14 (1) 11 - 18.

Brooks, N; Mchugh, PJ; Lee, M; Hartley, JA; (1999) Repair of DNA damage produced by sequence specific minor groove alkylating agent. PROC AM ASSOC CANCER RES , 40 p. 4118.

Burcombe, RJ; Ostler, PJ; Ayoub, AW; Hoskin, PJ; (1999) Staging CT scans in prostate cancer treatment: A retrospective audit. British Journal of Cancer , 80 p. 157.

C

Calabrese, CR; Thomas, HD; Batey, MA; Boritzki, T; Zhang, K; White, AW; Curtin, NJ; ... Newell, DR; + view all (1999) Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research , 5 543-.

Calvert, AH; Hughes, AN; Calvert, PM; Plummer, RE; Highley, MS; (1999) MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin. European Journal of Cancer , 35 1146-.

Calvert, AH; Sessa, C; Hughes, A; Jochim, U; Calvert, P; Ghielmini, M; Renard, J; ... Gallant, G; + view all (1999) Pharmacokinetics (PK) of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies. European Journal of Cancer , 35 1147-.

Calvert, H; (1999) MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Semin Oncol , 26 (2 Suppl 6) 105 - 108.

Calvert, H; (1999) MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Semin Oncol , 26 (2 Suppl ) pp. 105-108.

Calvert, PM; Highley, MS; Hughes, AN; Plummer, ER; Azzabi, AST; Verrill, MW; Camboni, MG; ... Calvert, AH; + view all (1999) A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors. Clinical Cancer Research , 5 333-.

Casey, JL; Pedley, RB; King, DJ; Boden, R; Chapman, AP; Yarranton, GT; Begent, RHJ; (1999) Improved tumour targeting of di-Fab ' fragments modified with polyethylene glycol. TUMOR TARGET , 4 (4) 235 - 244.

Casey, JL; Pedley, RB; King, DJ; Green, AJ; Yarranton, GT; Begent, RHJ; (1999) Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments. BRIT J CANCER , 81 (6) 972 - 980.

Cassoni, AM; Whelan, JS; (1999) Ewing's sarcoma: hyperfractionated radiotherapy with concurrent chemotherapy: acute toxicity. A prospective single institutional study. In: (pp. p. 45).

Chang, J; Powles, TJ; Allred, DC; Ashey, SE; Clark, GM; Makris, A; Assersohn, L; ... Dowsett, M; + view all (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. Journal Of Clinical Oncology , 17 pp. 3058-3063.

Chester, KA; Melton, RG; Hawkins, RR; (1999) Phage technology for producing antibody enzyme fusion proteins. In: Melton, RG and Fox, RJ, (eds.) Enzyme-Prodrug Strategies for Cancer Therapy. Klewer Academic/Plenum Press

Cooke, SP; Pedley, RB; Boden, R; Holliger, P; Winter, G; Begent, RHJ; Chester, KA; (1999) Tumour targeting using MFE-23 :: TNF alpha fusion protein. BRIT J CANCER , 80 85 - 85.

Cooke, SP; Pedley, RB; Boden, R; Holliger, P; Winter, G; Begent, RHJ; Chester, KA; (1999) Tumour targeting using MFE-23::TNF alpha fusion protein. British Journal of Cancer , 80 p. 228.

Cooke, SP; Pedley, RBB; R, H; P, W; G, B; R H J and Chester, KA; (1999) Tumour targeting using MFE::TNF fusion protein. In: (Proceedings) Proceedings BACR, Br J Cancer. (pp. 85-).

Cummins, D; Hoskin, P; Young, J; Goodman, IL; Coupe, MO; Halil, O; Foy, CJ; (1999) Is a man's facial appearance predictive of how he will die? International Journal of Clinical Practice , 53 pp. 140-141.

Curtin, NJ; Kyle, S; Wang, LZ; Durkacz, BW; White, AJ; Srinivasan, S; Griffin, RJ; ... Hostomsky, Z; + view all (1999) Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors. Clinical Cancer Research , 5 520-.

D

De Silva, IU; Clingen, PH; McHugh, PJ; Tilby, MJ; Gregson, SJ; Howard, P; Thurston, DE; (1999) The role of nucleotide excision repair in the repair of DNA damage induced by mono- and bifunctional, major and minor groove alkylating agents. BRIT J CANCER , 80 42 - 42.

DeSilva, IU; Clingen, PH; Mchugh, PJ; Tilby, MJ; Gregson, SJ; Howard, P; Thurston, DE; (1999) The role of nucleotide excision repair in the repair of DNA damage induced by mono- and bifunctional, major and minor groove alkylating agents. British Journal of Cancer , 80 p. 55.

Deighton, A; Winfield, EA; Venables, K; Aird, EGA; Hoskin, PJ; (1999) Variation in dose distribution for breast radiotherapy: A trial based quality assurance programme in the UK. European Journal of Cancer , 35 p. 342.

Delaney, CA; Wang, LZ; Kyle, LZ; Srinivasan, S; White, AW; Curtin, NJ; Calvert, AH; ... Newell, DR; + view all (1999) Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines. British Journal of Cancer , 80 62-.

Dische, S; Saunders, MI; (1999) The CHART regimen and morbidity [Full text available, price (Pounds)16.45]. Acta Oncologica , 38 pp. 147-152.

Dische, S; Saunders, MI; Sealy, R; Werner, ID; Verma, N; Foy, C; Bentzen, SM; (1999) Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: a report of a randomised controlled trial. Radiotherapy and Oncology , 53 pp. 93-98.

Dowsett, M; Smith, IE; Powles, TJ; Salter, J; Ellis, PM; Johnston, SRD; Makris, A; ... Assersohn, L; + view all (1999) Biological studies in primary medical therapy of breast cancer: The Royal Marsden Hospital experience. In: Howell, A and Dowsett, M, (eds.) ESO Scientific Updates. (pp. 113-125). Elsevier Science

E

Eardley, K; Majumdar, A; Ferrreira, MAS; Howie, AJ; Richards, NT; Savage, COS; Wheeler, DC; ... Lipkin, GW; + view all (1999) Microalbuminuria as a predictor of glomerular disease and renal prognosis in patients with microscopic haematuria. KIDNEY INT , 55 (6) 2586 - 2586.

F

Flynn, AA; Green, AJ; Boxer, G; Pedley, RB; Begent, RHJ; (1999) A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology. PHYS MED BIOL , 44 (7) N151 - N159.

Flynn, AA; Green, AJ; Boxer, GM; Casey, JL; Pedley, RB; Begent, RHJ; (1999) A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. INT J RADIAT ONCOL , 43 (1) 183 - 189.

Forster, M; Pande, K; de Takats, D; McCloskey, EV; de Vernijoul, MC; Taboulet, J; Frenkian, M; ... Kanis, JA; + view all (1999) Calcitonin gene receptor polymorphism is not associated with fracture risk factors in a random population sample. In: (pp. S231-S231). AMER SOC BONE & MINERAL RES

Frohlich, B; Paulussen, M; Craft, A; Judson, I; Ladenstein, R; Oberlin, O; Whelan, JS; ... Jurgens, HFEICESS92UE-E99; + view all (1999) Therapiekonzepte bei non-responden/rezidivpatienten mit Eing Sarkomen im kindesalter. In:

G

Gander, M; Hartley, JM; Spanswick, VJ; Webley, SD; Hochhauser, D; Hartley, JA; (1999) Measurment of DNA interstrand crosslinking in clinical samples using the single cell gel electrophoresis. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH , 40 p. 3410.

GlynneJones, R; Saunders, MI; Hoskin, P; Phillips, H; (1999) A pilot study of continuous, hyperfractionated, accelerated radiotherapy in rectal adenocarcinoma. Clinical Oncology , 11 pp. 334-339.

Goodchild, K; Hoskin, P; Dische, S; Pigott, K; Powell, M; Saunders, M; (1999) A feasibility study of continuous hyperfractionated accelerated radiotherapy (CHART) and brachytherapy in patients with early oral or oropharyngeal carcinomas. Radiotherapy and Oncology , 50 pp. 29-31.

Goodchild, KA; Hill, SA; Hoskin, PJ; Saunders, MI; Chaplin, DJ; (1999) Low dose nicotinamide and carbogen improve human tumour blood flow. British Journal of Cancer , 80 p. 244.

Gorodetsky, R; Lotan, C; Piggot, K; Pierce, LJ; Polyansky, I; Dische, S; Saunders, MI; ... Vexler, A; + view all (1999) Late effects of dose fractionation on the mechanical properties of breast skin following post-lumpectomy radiotherapy. International Journal of Radiation Oncology Biology Physics , 45 pp. 893-900.

Griffin, RJ; Barlow, HC; Curtin, NJ; Calvert, AH; Golding, BT; Newell, DR; Smith, PG; (1999) 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP). Clinical Cancer Research , 5 564-.

Grimaldi, KA; Bingham, JP; Hartley, JA; (1999) PCR-Based Assys for Strand-Specific Measurement of DNA Damage and Repair I. In: Henderson, DS, (ed.) Methods in Molecular Biology. (pp. 227-241). Humana Press Inc

Grimaldi, KA; Mac Adam, SR; Hartley, JA; (1999) PCR-Based Assys for Strand-Specific Measurement of DNA Damage and Repair II. In: Henderson, DS, (ed.) Methods in Molecular Biology. (pp. 241-255). Humana Press

H

Hoskin, PJ; Abdelath, O; Phillips, H; Gilligan, S; Saunders, MI; Broderick, P; Baddeley, H; (1999) Inspired and expired gas concentrations in man during carbogen breathing. Radiotherapy and Oncology , 51 pp. 175-177.

Hoskin, PJ; Saunders, MI; Abdellati, O; Broderick, P; (1999) Capnometry and blood gas measurements in man during carbogen breathing. British Journal of Cancer , 80 p. 328.

Hoskin, PJ; Saunders, MI; Dische, S; (1999) Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma - Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer , 86 pp. 1322-1328.

Hoskin, PJ; Saunders, MI; Goodchild, K; Powell, MEB; Taylor, NJ; Baddeley, H; (1999) Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. British Journal of Radiology , 72 pp. 1093-1098.

Hoskin, PJ; Stratford, M; Folkes, L; Phillips, H; Jackson, S; Regan, J; Yarnold, JR; (1999) Bone markers in response to local radiotherapy for bone pain. British Journal of Cancer , 80 p. 28.

Hughes, AN; Rafi, I; Griffin, MJ; Calvert, AH; Newell, DR; Calvete, JA; Johnston, A; ... Boddy, AV; + view all (1999) Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. CLIN CANCER RES , 5 (1) 111 - 118.

Hunalov, A; Robson, L; Perkins, SJ; Begent, RHJ; Chester, KA; (1999) A vector for expression of dimeric and chelating forms of anti-CEA scFvS. British Journal of Cancer , 80 p. 92.

Hunalov, A; Robson, L; Perkins, SJ; Begent, RHJ; Chester, KA; (1999) A vector for expression of dimeric and chelating forms of anti-CEA scFvS. BRIT J CANCER , 80 51 - 51.

J

Joiner, MC; Marples, B; Lambin, P; Short, S; Turesson, I; (1999) Low-dose hypersensitivity: current status and possible mechanisms. International Journal of Radiation Oncology Biology Physics , 49 (2) pp. 379-389.

K

Kiani-Alikhan, S; Chester, KA; Ledermann, JA; Beverley, PCL; (1999) Potentiation of the activity of dendritic cells by DNA. In: (pp. p. 93).

Kiani-Alikhan, S; Chester, KA; Ledermann, JA; Beverley, PCL; (1999) Potentiation of the activity of dendritic cells by DNA. BRIT J CANCER , 80 52 - 52.

M

Majumdar, A; Eardley, K; Howie, AJ; Savage, COS; Wheeler, DC; Richards, NT; Adu, D; (1999) Prevalence, predictors and prognostic significance of non-diabetic renal disease (NDRD) in patients with type II diabetes mellitus (NIDM). KIDNEY INT , 55 (6) 2592 - 2592.

Makris, A; Powles, TJ; Allred, DC; Ashley, SE; Trott, PA; Ormerod, MG; Titley, JC; (1999) Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study. Breast Cancer Research And Treatment , 53 pp. 51-59.

Makris, A; Powles, TJ; Kakolyris, S; Dowsett, M; Ashley, SE; Harris, AL; (1999) Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer , 85 pp. 1996-2000.

Mayer, A; Chester, KA; Flynn, AA; Begent, RH; (1999) Taking engineered anti-CEA antibodies to the clinic. J Immunol Methods , 231 (1-2) pp. 261-273.

McHugh, PJ; Gill, RD; Waters, R; Hartley, JA; (1999) Excision repair of nitrogen mustard-DNA adducts in Saccharomyces cerevisiae. NUCLEIC ACIDS RES , 27 (16) 3259 - 3266. Gold open access

McHugh, PJ; Hartley, JA; (1999) The induction and repair of DNA doublestrand breaks in nitrogen mustard treated Saccharomyces cerevisiae cells. BRIT J CANCER , 80 42 - 42.

Mchugh, PJ; Hartley, JA; (1999) The induction and repair of DNA doublestrand breaks in nitrogen mustard treated Saccharomyces cerevisiae cells. British Journal of Cancer , 80 p. 54.

N

Napier, MP; Hoare, D; Whelan, JS; (1999) Safe administration of high dose methotrexate in osteosarcoma: Carboxypeptidase G2 for idiosynchratic toxicity. British Journal of Cancer , 80 p. 155.

Napier, NP; Hoare, D; Whelan, JS; (1999) Safe administration of high dose methotrexate in osteosarcoma: carboxypeptidase G2 for idiosyncratic toxicity. In:

Newby, JC; Leonard, P; Fenwick, E; Harland, SJ; (1999) A phase II study of epirubicin, carboplatin and infusional 5-FU in hormone resistant prostate cancer. British Journal of Cancer , 80 p. 158.

Newell, DR; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, P; Endicott, JA; ... Schultz, R; + view all (1999) Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Clinical Cancer Research , 5 124-.

Newell, DR; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, P; Endicott, JA; ... Schultz, R; + view all (1999) Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. CLIN CANCER RES , 5 3755S - 3755S.

Ng, T; (1999) Imaging Protein Kinase C Activation in Cells. Science , 283 (5410) pp. 2085-2089. 10.1126/science.283.5410.2085.

O

Osborne, M; GlynneJones, R; Galbraith, S; Burcombe, R; Makris, A; (1999) Squamous cell carcinoma antigen as a marker of epidermoid carcinoma of the anal canal. British Journal of Cancer , 80 p. 117.

Osborne, M; GlynneJones, R; Hoskin, P; Saunders, M; Makris, A; (1999) Continuous hyperfractionated accelerated radiotherapy +/-concurrent infusional 5FU in advanced rectal cancer. British Journal of Cancer , 80 p. 114.

Osbourn, JK; McCafferty, J; Derbyshire, EJ; Waibel, R; Chester, K; Boxer, G; Allen, D; (1999) Isolation of a panel of human anti-CEA single chain Fv from a large phage display library. Tumor Targeting , 4 pp. 150-157.

P

Paniwnyk, Z; Pors, K; TeesdaleSpittle, PH; Potter, GA; Plumb, J; Hartley, JA; Patterson, LH; (1999) Novel inhibitor of topo II is effective against resistant ovarian cancer cells. British Journal of Cancer , 80 p. 69.

Parkinsoin, MC; Harland, SJ; (1999) Testis cancer. In: Mundy, AR and Fitzpatrick, JM and Neal, DE and George, NJR, (eds.) Scientific Basis of Urology. (pp. 375-394). Isis Medical Media Ltd: Oxford, UK.

Pedley, RB; Sharma, SK; Boxer, GM; Boden, R; Stribbling, SM; Davies, L; Springer, CJ; (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res , 59 (16) pp. 3998-4003.

Pedley, RB; Sharma, SK; Boxer, GM; Boden, R; Stribbling, SM; Davies, L; Springer, CJ; (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. CANCER RES , 59 (16) 3998 - 4003.

Plummer, R; Rees, C; Judson, I; Calvert, H; Highley, M; Trigo, J; Jackman, A; ... Smith, M; + view all (1999) Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks. EUR J CANCER , 35 S285 - S285.

Powell, MEB; Collingridge, DR; Saunders, MI; Hoskin, PJ; Hill, SA; Chaplin, DJ; (1999) Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiotherapy and Oncology , 50 pp. 167-171.

S

Shamash, J; Lee, SM; Deakin, DP; Scarffe, JH; Morgenstern, GR; Chang, J; Gupta, RK; ... Lister, TA; + view all (1999) High dose chemotherapy (HDCT) with autologous haematopoietic support in recurrent or refractory Hodgkin’s lymphoma (HL). In: (Proceedings) British Cancer Research Meeting, Edinburgh.. (pp. 18-). British Journal of Cancer

Short, S; (1999) UNSPECIFIED In: (Proceedings) The Royal College of Radiologists Annual Scientific Meeting.

Short, S; (1999) The response of human glioma cells to low dose radiation. International journal of radiation biology , 75 pp. 1341-1348.

Short, S; Mayes, C; Woodcock, M; Joiner, MC; (1999) Low-dose hypersensitivity in the T98G glioblastoma cell line. International journal of radiation biology , 75 pp. 847-855.

Smith, PG; Barlow, HC; Loughlin, P; Huang, B; Bowman, KJ; Calvert, AH; Curtin, NJ; ... Newell, DR; + view all (1999) Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein. British Journal of Cancer , 80 82-.

Smith, PG; Bewley, J; Gogel, JA; Calvert, AH; Newell, DR; Curtin, NJ; Chen, VJ; (1999) MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines. British Journal of Cancer , 80 83-.

Spanswick, VJ; Hartley, JM; Ward, TH; Hartley, JA; (1999) Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay. Methods Mol Med , 28 pp. 143-154. 10.1385/1-59259-687-8:143.

Spencer, DIR; Robson, L; Bhatia, J; Sharma, SK; Michael, NP; Whitelegg, NR; Rees, AR; ... Begent, RHJ; + view all (1999) Identifying immunogenic sites on adept enzymes CPG2 using a SCFV phage library & SELDI (TM)-AMS. In: (pp. p. 94).

Spencer, DIR; Robson, L; Bhatia, J; Sharma, SK; Michael, NP; Whitelegg, NR; Rees, AR; ... Bergent, RHJ; + view all (1999) Identifying immunogenic sites on adept enzymes CPG2 using a SCFV phage library & SELDI (TM)-AMS. BRIT J CANCER , 80 52 - 52.

Steingruber, HE; Dunham, A; Coffey, AJ; Clegg, SM; Howell, GR; Maslen, GL; Scott, CE; ... Ross, MT; + view all (1999) High-resolution landmark framework for the sequence-ready mapping of Xq23-q26.1. GENOME RES , 9 (8) 751 - 762.

Strauss, S; McTiernan, A; Whelan, JS; (1999) Recurrence of osteosarcoma after disease-free intervals exceeding 5 years. In:

Summers, Y; Middleton, MR; Calvert, H; Lee, SM; Rustin, R; Newell, DR; Thatcher, N; (1999) Effect of temozolomide (TMZ) on central nervous system relapse in patients with advanced melanoma. In: (Proceedings) 1999 ASCO Annual Meeting/35th Annual Meeting, Atlanta, GA.. (pp. 531a-). Proceedings of the American Society of Clinical Oncology

V

Vanhaesebroeck, B; Higashi, K; Raven, C; Welham, M; Anderson, S; Brennan, P; Ward, SG; (1999) Autophosphorylation of p110 delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. EMBO JOURNAL , 18 (5) pp. 1292-1302. 10.1093/emboj/18.5.1292.

Vanhaesebroeck, B; Higashi, K; Raven, C; Welham, M; Anderson, S; Brennan, P; Ward, SG; (1999) Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. The EMBO Journal , 18 (5) pp. 1292-1302.

W

Webley, SD; Francis, R; Begent, RHJ; Hartley, JA; Hochhauser, D; (1999) Measurement of the critical DNA lesions produced by antibody directed enzyme prodrug therapy (ADEPT). BRIT J CANCER , 80 47 - 47.

Wedderburn, LR; Maini, MK; Patel, A; Beverley, PCL; Woo, P; (1999) Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood. INT IMMUNOL , 11 (4) 535 - 543.

Whelan, JS; Goodchild, K; Strauss, S; McTiernan, A; Driver, D; Kilby, AM; Cassoni, AM; (1999) Intensive induction therapy (VIDE) including stem cell collection for Ewing's family of tumours. In:

Woll, PJ; Carmichael, J; Chan, S; Howell, A; Ranson, M; Miles, D; Calvert, H; (1999) Phase II study results on safety and efficacy of CAELYX (R) (DOXIL (R)) in combination with paclitaxel in the treatment of metastatic breast cancer. EUR J CANCER , 35 S322 - S322.

This list was generated on Sun Jun 17 01:46:24 2018 BST.